靶向和免疫治疗原发性肝癌:肝移植术前降期治疗应用进展*

doi:10.3969/j.issn.1672-5069.2024.06.003

Abstract

Zhu Zebin, Zhang Shugeng, Liu Lianxin. Targeted therapy and immunotherapy in downstaging of patients with hepatocellular carcinoma before liver transplantation[J]. Journal of Practical Hepatology, 2024, 27(6): 808-811.

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021,71(3):209-249.
[2] Imamura J, Tateishi R, Shiina S, et al. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol, 2008, 103(12):3057-3062.
[3] 郑树森, 董家鸿, 窦科峰,等. 中国肝癌肝移植临床实践指南(2021年版). 中华移植杂志(电子版), 2021, 15(6):321-328.
[4] Tran NH, Muñoz S, Thompson S, et al. Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy. Hepatology, 2022, 76(4):1203-1218.
[5] Golse N, Radenne S, Rode A, et al. Liver transplantation after neoadjuvant sorafenib therapy: Preliminary experience and literature review. Exp Clin Transplant, 2018, 16(2):227-236.
[6] Frenette CT, Boktour M, Burroughs SG, et al. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. Transpl Int, 2013,26(7):734-739.
[7] 鲁旭, 李华, 易述红,等. 介入联合仑伐替尼桥接治疗超米兰标准肝癌肝移植2例报道. 岭南现代临床外科, 2021, 21(5):507-511.
[8] Eilard MS, Andersson M, Naredi P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. BMC Cancer, 2019, 19(1):568.
[9] Schwacha-Eipper B, Minciuna I, Banz V, et al. Immunotherapy as a downstaging therapy for liver transplantation. Hepatology, 2020, 72(4):1488-1490.
[10] Schnickel GT, Fabbri K, Hosseini M, et al. Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab. Am J Transplant, 2022,22(6):1699-1704.
[11] Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation? Am J Transplant, 2021, 21(5):1979-1980.
[12] Wang T, Chen Z, Liu Y, et al. Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss. Liver Transpl, 2023, 29(6):598-606.
[13] Wang Y, Jiang M, Zhu J, et al. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomed Pharmacother, 2020,132:110797.
[14] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med, 2020, 382(20):1894-1905.
[15] Qiao ZY, Zhang ZJ, Lv ZC, et al. Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: A cohort study and literature review. Front Immunol, 2021, 12:653437.
[16] Schmiderer A, Zoller H, Niederreiter M, et al. Liver transplantation after successful downstaging of a locally advanced hepatocellular carcinoma with systemic therapy. Dig Dis, 2023, 41(4):641-644.
[17] Giudicelli H, Roux C, Monsel A, et al. Successful advanced hepatocellular carcinoma downstaging with atezolizumab-Bevacizumab and radioembolization before liver transplantation. Clin Res Hepatol Gastroenterol, 2023, 47(7):102167.
[18] Chiang CL, Chiu KWH, Chan KSK, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol, 2023, 8(2):169-178.
[19] Brown ZJ, Hewitt DB, Pawlik TM. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Expert Opin Investig Drugs, 2022, 31(4):379-391.
[20] Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol, 2017, 66(3):545-551.
[21] Harding JJ, Nandakumar S, Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res, 2019, 25(7):2116-2126.
[22] Adebayo Michael AO, Ko S, Tao J, et al. Inhibiting glutamine-dependent mTORC1 activation ameliorates liver cancers driven by β-catenin mutations. Cell Metab, 2019,29(5):231-236.
[23] Mizukoshi E, Kaneko S. Immune cell therapy for hepatocellular carcinoma. J Hematol Oncol,2019,12(1):52.

Targeted therapy and immunotherapy in downstaging of patients with hepatocellular carcinoma before liver transplantation

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Shaobo, Zhang Shugeng, Liu Lianxin. Immunotherapy in hepatocellular carcinoma patients after liver transplantation:Current knowledge and future perspectives [J]. Journal of Practical Hepatology, 2024, 27(6): 801-803.
[2]	Zheng Hao, Zhang Shugeng, Wang Jiabei, et al. Therapeutic strategies for patients with recurrent hepatocellular carcinoma after liver transplantation [J]. Journal of Practical Hepatology, 2024, 27(6): 804-807.
[3]	Zeng Wang, Cai Xiaoman, Ge Shang. Enhanced MRI manifestation feature in differential diagnosis of ICC and HCC: A single center study [J]. Journal of Practical Hepatology, 2024, 27(6): 907-910.
[4]	Danba Yuzhen, Cheng Pan. Gd-EOB-DTPA-enhanced MRI scan in diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 911-914.
[5]	Yang Jiaxin, Yang Zijun, Chen Wei. Image quality and diagnostic efficacy of dual-source CT dual-energy TNC technique in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 915-918.
[6]	Wang Lingling, Yao Min, Yao Dengfu. Abnormal expressions of Krüppel-like factors in progression of hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 953-956.
[7]	Li Xiaobin, Liu Bowen, Hu shiping. Lipid metabolic reprogramming in the carcinogenesis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 957-960.
[8]	Zhang Weiping, Ge Hongyan. Pyroptosis and its roles in hepatocellular carcinogenesis [J]. Journal of Practical Hepatology, 2024, 27(5): 797-800.
[9]	Luo Ke, Ding Li, Liu Mei. Cancerous expression of TTF-1, p53 and p63 proteins in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(3): 434-437.
[10]	Yan Zhen, Zhao Bowen, Lin Guoying, et al. Clinical application of imaging three-dimensional visualization technique in guidance of hepatectomy in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(3): 438-441.
[11]	Xu Xu, Shi Yiwen, Fan Jiangao. Treatment of hepatolenticular degeneration:Status and prospective [J]. Journal of Practical Hepatology, 2024, 27(3): 477-480.
[12]	Wei Ye, Wang Shiyu, Ge Gaohua, et al.. Is the magnetic resonance imaging superior to CT scan in the differential diagnosis of hepatic hemangioma and hepatocellular carcinoma? [J]. Journal of Practical Hepatology, 2024, 27(2): 279-282.
[13]	Ye Mengmeng, Deng Zerun, Zhang Tao. Improved benefit of camrelizumab and apatinib combination in the treatment of patients with advanced hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(1): 96-100.
[14]	Zhou Li, Ding Yunqing, Yuan Fengying, et al. Diagnostic performance of contrast-enhanced ultrasound in determining qualitatively intrahepatic space-occupying lesions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(6): 903-906.
[15]	Zhang Shugeng, Zhang Shaobo, Zhu Zebin, et al. Early post-operational complications in patients with orthotopic liver transplantation receiving different deceased donors [J]. Journal of Practical Hepatology, 2023, 26(5): 738-741.